

Capecitabine Monotherapy

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Treatment of patients with locally advanced or metastatic breast cancer	C50	00216a	CDS
Treatment of metastatic colorectal cancer	C18	00216b	CDS
Adjuvant treatment of patients following surgery of stage III colon cancer	C18	00216c	CDS
Adjuvant treatment of patients following surgery of stage II colon cancer ⁱ	C18	00216d	CDS
Adjuvant treatment of patients with metastatic colorectal cancer following complete resection ⁱ	C18	00216e	CDS
Adjuvant treatment of stage I to IIIB, triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment ⁱ	C50	00216f	CDS

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Capecitabine is administered twice daily for two weeks (days 1-14) followed by a 7 day rest period on days 15-21. This 21 day (3-week) period is considered a treatment cycle.

Adjuvant treatment in patients with colon or triple negative breast cancer is recommended for a total of 6 months (8 cycles).

Treatment for metastatic disease is until disease progression or unacceptable toxicity develops.

Day	Drug	Dose	Route	Cycle
1-14	Capecitabine	1250mg/m ² Twice Daily ^{a,b,c,d}	PO with food	Every 21 days
^a The dose to be administered should consider the available tablet strengths. Reference to the NCCP DOSE BANDING TABLES for dosing of capecitabine Here . Tablets should be swallowed whole with plenty of water with food or within 30 minutes of eating. Tablets should not be crushed or cut.				
^b (total daily dose = 2500mg/m ²)				
^c Starting dose of 1000 mg/m ² twice daily may be considered for elderly patients, patients with a poor performance status or extensively pretreated patients.				
^d See dose modifications section for patients with identified partial DPD deficiency.				

ELIGIBILITY:

- Indications as above
- ECOG status 0-2

NCCP Regimen: Capecitabine Monotherapy	Published: 10/01/2015 Review: 08/01/2025	Version number: 7
Tumour Group: Breast/Gastrointestinal NCCP Regimen Code: 00216	ISMO Contributor: Prof Maccon Keane	Page 1 of 1
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens		

EXCLUSIONS:

- Hypersensitivity to capecitabine or any of the excipients
- Known complete DPD deficiency
- History of severe and unexpected reactions to fluoropyrimidine therapy
- Pregnancy and lactation
- Severe hepatic or renal impairment
- Recent or concomitant treatment with brivudine

PRESCRIPTIVE AUTHORITY:

- The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:

Baseline tests:

- FBC, renal and liver profile
- DPD testing prior to first treatment with capecitabine using phenotype and/or genotype testing unless patient has been previously tested

Regular tests:

- FBC, renal and liver profile prior to each cycle.

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Consider a reduced starting dose in patients with identified partial DPD deficiency
 - Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring
- Any dose modification should be discussed with a Consultant
- Toxicity due to capecitabine administration may be managed by symptomatic treatment and/or modification of the dose (treatment interruption or dose reduction)
- Once the dose has been reduced, it should not be increased at a later time
- For those toxicities considered by the treating physician to be unlikely to become serious or life-threatening, e.g. alopecia, altered taste, nail changes, treatment can be continued at the same dose without reduction or interruption
- Patients taking capecitabine should be informed of the need to interrupt treatment immediately if moderate or severe toxicity occurs
- Doses of capecitabine omitted for toxicity are not replaced

NCCP Regimen: Capecitabine Monotherapy	Published: 10/01/2015 Review: 08/01/2025	Version number: 7
Tumour Group: Breast/Gastrointestinal NCCP Regimen Code: 00216	ISMO Contributor: Prof Maccon Keane	Page 2 of 2

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Haematological:

- Initiation of treatment with capecitabine in patients with baseline neutrophil counts $<1.5 \times 10^9/L$ and/or thrombocyte counts of $<100 \times 10^9/L$ should be undertaken with caution.
- If unscheduled laboratory assessments during a treatment cycle show that the neutrophil count drops below $1 \times 10^9/L$ or that the platelet count drops below $75 \times 10^9/L$, treatment with capecitabine should be interrupted.

Table 1: Dose modification of capecitabine based on haematological toxicity

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	1st Event Dose	2 nd Event Dose	3 rd Event Dose	4 th Event Dose
≥ 1.5	and	≥ 75	100%	100%	100%	100%
1-1.49	or	50 – 74.9	Delay* then 100%	Delay* then 75%	Delay* then 50%	Discontinue
0.5-0.99	or	25- 49.9	Delay* then 75%	Delay* then 50%	Discontinue	Discontinue
< 0.5	or	< 25	Discontinue or delay* then 50%	Discontinue	Discontinue	Discontinue

*Delay until ANC ≥ $1.5 \times 10^9/L$ and platelets ≥ $75 \times 10^9/L$

Renal and Hepatic Impairment:

Table 2: Dose modification of capecitabine in renal and hepatic impairment

Renal Impairment		Hepatic Impairment*
CrCl (ml/min)	Dose	In the absence of safety and efficacy data in patients with hepatic impairment, capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis.
51-80	100% dose	
30-50	Reduce starting dose to 75% if on $1250 \text{mg}/\text{m}^2$ dose. No change if on $1000 \text{mg}/\text{m}^2$ dose	
<30	Discontinue treatment	

*Reference Table 6 - for dose modification of capecitabine in treatment related hepatotoxicity

NCCP Regimen: Capecitabine Monotherapy	Published: 10/01/2015 Review: 08/01/2025	Version number: 7
Tumour Group: Breast/Gastrointestinal NCCP Regimen Code: 00216	ISMO Contributor: Prof Maccon Keane	Page 3 of 3
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Management of adverse events:

Table 3 shows the recommended dose modifications of capecitabine for those toxicities which are not individually specified:

Table 3: Capecitabine dose reduction schedule (three weekly cycle) based on toxicity

Toxicity grades*	Dose changes within a treatment cycle	Dose adjustment for next cycle/dose (% of starting dose)
Grade 1	Maintain dose level	Maintain dose level
Grade 2	Interrupt until resolved to grade 0-1	
• 1 st appearance		100%
• 2 nd appearance		75%
• 3 rd appearance		50%
• 4 th appearance	Discontinue permanently	
Grade 3	Interrupt until resolved to grade 0-1	
• 1 st appearance		75%
• 2 nd appearance		50%
• 3 rd appearance	Discontinue permanently	
Grade 4	Discontinue permanently or If consultant deems it to be in patient's best interest to continue, interrupt until resolved to grade 0-1	50%
• 1 st appearance		
• 2 nd appearance	Discontinue permanently	
Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy.		

*Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

NCCP Regimen: Capecitabine Monotherapy	Published: 10/01/2015 Review: 08/01/2025	Version number: 7
Tumour Group: Breast/Gastrointestinal NCCP Regimen Code: 00216	ISMO Contributor: Prof Maccon Keane	Page 4 of 4
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Table 4: Dose Modification of capecitabine for diarrhoea

Grade	Diarrhoea	Dose changes within a treatment cycle	Dose adjustment for next cycle/dose (% of starting dose)
0-1	Increase of 2 to 3 stools/day or nocturnal stools	Maintain dose level	Maintain dose level
2	Increase of 4 to 6 stools/day or nocturnal stools	Interrupt until resolved to grade 0-1	100%
	• 1 st appearance		
	• 2 nd appearance		
	• 3 rd appearance		
	• 4 th appearance	Discontinue permanently	50%
3	Increase of 7 to 9 stools/day or incontinence	Interrupt until resolved to grade 0-1	75%
	• 1 st appearance		
	• 2 nd appearance	50%	
	• 3 rd appearance	Discontinue permanently	
4	Increase of 10 or more stools/day or grossly bloody diarrhoea; may require parenteral support		
	• 1 st appearance	Discontinue permanently or If consultant deems it to be in patient's best interest to continue, interrupt until resolved to grade 0-1	50%
	• 2 nd appearance	Discontinue permanently	

Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy.

Hand foot syndrome:

Table 5: Dose modification of capecitabine in hand foot syndrome

Toxicity Grade		Dose Modification
Grade 1	Skin changes (e.g., numbness, dysesthesia, paresthesia, tingling, erythema) with discomfort not disrupting normal activities	100% Dose
Grade 2	Skin changes (e.g., erythema, swelling) with pain affecting activities of daily living	Withhold treatment until event resolves or decreases in intensity to grade 1.
Grade 3	Severe skin changes (e.g., moist desquamation, ulceration, blistering) with pain, causing severe discomfort and inability to work or perform activities of daily living	Withhold treatment until event resolves or decreases in intensity to grade 1. Subsequent doses of capecitabine should be decreased

NCCP Regimen: Capecitabine Monotherapy	Published: 10/01/2015 Review: 08/01/2025	Version number: 7
Tumour Group: Breast/Gastrointestinal NCCP Regimen Code: 00216	ISMO Contributor: Prof Maccon Keane	Page 5 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Treatment related hepatotoxicity

Table 6: Dose modification of capecitabine in treatment related hepatotoxicity

Bilirubin		ALT, AST	Dose Modification
> 3.0 x ULN	or	> 2.5 x ULN	Withhold treatment until bilirubin decreases to ≤ 3.0 x ULN or ALT, AST decrease to ≤ 2.5 x ULN

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Minimal to low (Refer to local policy).

PREMEDICATIONS: Not usually required

OTHER SUPPORTIVE CARE:

Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS:

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Diarrhoea and dehydration:** This may be dose limiting. Patients with severe diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated.
- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Cardiotoxicity:** Angina-like chest pain, tachycardia, arrhythmias, heart failure, myocardial infarction and cardiac arrest may occur with capecitabine especially in patients with a prior history of coronary artery disease.
- **Dihydropyrimidine dehydrogenase (DPD) deficiency:** DPD is an enzyme encoded by the DPYD gene which is responsible for the breakdown of fluoropyrimidines. Patients with DPD deficiency are therefore at increased risk of fluoropyrimidine-related toxicity, including for example stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity. Treatment with 5-Fluorouracil, capecitabine or tegafur-containing medicinal products is contraindicated in patients with known complete DPD deficiency. Consider a reduced starting dose in patients with identified partial DPD deficiency. Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring. Therapeutic drug monitoring (TDM) of fluorouracil may improve clinical outcomes in patients receiving continuous 5-fluorouracil infusions.
- **Hand-foot syndrome (HFS):** HFS, also known as palmar-plantar erythrodysesthesia (PPE), is a common side effect associated with capecitabine (see Table 5 for dose modification of capecitabine for HFS).

NCCP Regimen: Capecitabine Monotherapy	Published: 10/01/2015 Review: 08/01/2025	Version number: 7
Tumour Group: Breast/Gastrointestinal NCCP Regimen Code: 00216	ISMO Contributor: Prof Maccon Keane	Page 6 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

DRUG INTERACTIONS:

- Capecitabine enhances the anticoagulant effect of warfarin. Patients taking coumarin derivative anticoagulants should be monitored regularly for alterations in their coagulation parameters and the anti-coagulant dose adjusted accordingly.
- Brivudine must not be administered concomitantly with capecitabine. Fatal cases have been reported following this drug interaction. There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy.
- Patients taking phenytoin or fosphenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.
- Current drug interaction databases should be consulted for more information.

REFERENCES:

1. Hirsch BR and Zafar SY. Capecitabine in the management of colorectal cancer. *Cancer Manag Res.* 2011; 3: 79–89.
2. Marshall JL, Haller DG et al. Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. *Gastrointestinal Cancer Research* 2007; 1 (4) 146-154.
3. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. *Oncologist.* 2006; 11(4):325-35.
4. Gelmon K, Chan A and Harbeck, N. The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer. *The Oncologist* 2006, 11:42-51.
5. O’Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. *Ann Oncol* 2001; 12: 1247–1254.
6. Twelves C, Wong A. et al. Capecitabine as adjuvant treatment for stage III colon cancer. *NEJM* 2005; 352 (26):2696-2704.
7. Blum JL, Jones SE et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. *J Clin Oncol* 1999; 17:485-93.
8. Hoff PM, Ansari R, Batist G et al. Comparison of Oral Capecitabine Versus Intravenous fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomised Phase III Study. *J Clin Onc.* 2001;19; 2282 – 2292.
9. Masuda N, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. *N Engl J Med* 2017; 376:2147-2159
10. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network.
11. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network.
12. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V4 2022. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
13. Capecitabine (Xeloda®) Summary of Product Characteristics. Last updated: 28/08/2019. Accessed July 2022. Available at: https://www.ema.europa.eu/en/documents/product-information/xeloda-epar-product-information_en.pdf

NCCP Regimen: Capecitabine Monotherapy	Published: 10/01/2015 Review: 08/01/2025	Version number: 7
Tumour Group: Breast/Gastrointestinal NCCP Regimen Code: 00216	ISMO Contributor: Prof Maccon Keane	Page 7 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

14. HPRA Direct Healthcare Professional Communication. 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity. Accessed Aug 2020 Available at: [https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-\(i-v\)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0](https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-(i-v)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0)

Version	Date	Amendment	Approved By
1	10/01/2015		Prof Maccon Keane
2	11/01/2017	Amended wording in exclusions with respect to DPD deficiency, Updated prescribing authority,	Prof Maccon Keane
3	19/12/2017	Applied new NCCP regimen template, clarified toxicity criteria for diarrhea and hand-foot syndrome	Prof Maccon Keane
4	08/01/2020	Reviewed. Update of drug interactions, exclusion criteria	Prof Maccon Keane
5	20/08/2020	Updated exclusion criteria, baseline testing, dose modifications and adverse events with respect to DPD deficiency as per DHPC from HPRA June 2020 Updated Adverse events regarding palmar-plantar erythrodysesthesia	Prof Maccon Keane
6	24/08/2022	New indication added	Prof Maccon Keane
7	18/01/2023	Amended emetogenic potential	Prof Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ⁱ This is an unlicensed indication for the use of capecitabine in Ireland. Patients should be informed of the unlicensed nature of this indication and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or "off label" indications. Prescribers should be aware of their responsibility in communicating any relevant information to the patient and also in ensuring that the unlicensed or "off label" indication has been acknowledged by the hospital's Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

NCCP Regimen: Capecitabine Monotherapy	Published: 10/01/2015 Review: 08/01/2025	Version number: 7
Tumour Group: Breast/Gastrointestinal NCCP Regimen Code: 00216	ISMO Contributor: Prof Maccon Keane	Page 8 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		